X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11280) 11280
Newsletter (330) 330
Newspaper Article (189) 189
Magazine Article (126) 126
Book Review (7) 7
Book Chapter (5) 5
Dissertation (3) 3
Transcript (3) 3
Web Resource (3) 3
Conference Proceeding (1) 1
Publication (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10985) 10985
hiv infections - drug therapy (8011) 8011
anti-hiv agents - adverse effects (6644) 6644
anti-hiv agents - therapeutic use (6523) 6523
female (5917) 5917
male (5709) 5709
adult (5135) 5135
hiv (4049) 4049
infectious diseases (3995) 3995
middle aged (3354) 3354
anti-hiv agents - administration & dosage (2895) 2895
antiretroviral therapy (2456) 2456
immunology (2443) 2443
antiviral agents (2426) 2426
hiv infection (2001) 2001
drug therapy, combination (1983) 1983
hiv infections - complications (1917) 1917
aids (1837) 1837
pharmacology & pharmacy (1796) 1796
drug therapy (1787) 1787
human immunodeficiency virus--hiv (1753) 1753
cd4 lymphocyte count (1612) 1612
treatment outcome (1580) 1580
viral load (1568) 1568
risk factors (1555) 1555
hiv infections - virology (1539) 1539
anti-hiv agents (1431) 1431
highly active antiretroviral therapy (1424) 1424
virology (1400) 1400
health aspects (1260) 1260
antiretroviral drugs (1252) 1252
hiv-1 - drug effects (1157) 1157
reverse transcriptase inhibitors - adverse effects (1139) 1139
adolescent (1126) 1126
therapy (1119) 1119
protease inhibitors (1093) 1093
research (1083) 1083
hiv-1 (1080) 1080
antiretroviral therapy, highly active (1076) 1076
human-immunodeficiency-virus (1070) 1070
antiretroviral therapy, highly active - adverse effects (1052) 1052
pregnancy (1050) 1050
young adult (1023) 1023
tenofovir (1021) 1021
microbiology (1016) 1016
reverse transcriptase inhibitors - therapeutic use (998) 998
hiv infections - prevention & control (994) 994
hiv infections - immunology (974) 974
aids/hiv (947) 947
care and treatment (937) 937
anti-hiv agents - pharmacology (932) 932
hiv patients (921) 921
drug interactions (912) 912
anti-hiv agents - pharmacokinetics (893) 893
infection (889) 889
aged (872) 872
hiv infections - epidemiology (850) 850
acquired immune deficiency syndrome--aids (843) 843
human immunodeficiency virus (795) 795
analysis (774) 774
adenine - analogs & derivatives (770) 770
retrospective studies (764) 764
cohort studies (755) 755
medicine, general & internal (739) 739
hiv infections - transmission (738) 738
hiv protease inhibitors - adverse effects (720) 720
active antiretroviral therapy (712) 712
efavirenz (705) 705
prospective studies (699) 699
drug administration schedule (692) 692
zidovudine (691) 691
prevention (679) 679
animals (664) 664
dosage and administration (659) 659
pharmacokinetics (658) 658
child (640) 640
hiv protease inhibitors - therapeutic use (636) 636
safety (634) 634
public, environmental & occupational health (633) 633
hiv/aids (630) 630
mortality (616) 616
hiv-infected patients (602) 602
research article (601) 601
acquired immunodeficiency syndrome - drug therapy (595) 595
infant, newborn (581) 581
medicine (567) 567
prevalence (567) 567
adherence (566) 566
time factors (566) 566
risk (561) 561
virus diseases (546) 546
nevirapine (545) 545
antiretroviral agents (543) 543
medicine & public health (523) 523
pregnancy complications, infectious - drug therapy (523) 523
drugs (519) 519
zidovudine - therapeutic use (519) 519
adenine - adverse effects (511) 511
zidovudine - adverse effects (508) 508
infected patients (505) 505
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11100) 11100
German (338) 338
Spanish (230) 230
French (157) 157
Japanese (28) 28
Dutch (22) 22
Italian (21) 21
Portuguese (21) 21
Chinese (18) 18
Danish (18) 18
Russian (15) 15
Norwegian (8) 8
Polish (8) 8
Hebrew (5) 5
Swedish (5) 5
Turkish (3) 3
Czech (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | VAGINAL GEL | INDIVIDUALS | SOUTH-AFRICA | PROPHYLAXIS | IN-VITRO | TRANSMISSION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | MALE CIRCUMCISION | RANDOMIZED CONTROLLED-TRIAL | CHALLENGES | HIV Infections - prevention & control | Anti-Infective Agents, Local - therapeutic use | Urban Population - statistics & numerical data | HIV Infections - epidemiology | Humans | Anti-Infective Agents, Local - adverse effects | Drug Resistance, Viral | Administration, Intravaginal | Viral Load | Incidence | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Adenine - adverse effects | HIV-1 - physiology | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Vaginal Creams, Foams, and Jellies | Rural Population - statistics & numerical data | Sexual Behavior | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | South Africa - epidemiology | Organophosphonates - adverse effects | Adenine - administration & dosage | Pregnancy | Organophosphonates - administration & dosage | Anti-Infective Agents, Local - administration & dosage | Adolescent | Patient Compliance | Pregnancy Outcome | Prevention | Anti-infective agents | Research | HIV infection
Journal Article
PLoS pathogens, ISSN 1553-7374, 2015, Volume 11, Issue 9, p. e1005142
Pharmacologically-induced activation of replication competent proviruses from latency in the presence of antiretroviral treatment (ART) has been proposed as a... 
ACTIVATION | RNA | PERSISTENCE | CD4(+) T-CELLS | MICROBIOLOGY | VIROLOGY | HISTONE DEACETYLASES | ACTIVE ANTIRETROVIRAL THERAPY | IMMUNODEFICIENCY-VIRUS TYPE-1 | STEM-CELL | INFECTION | PARASITOLOGY | VIRAL RESERVOIR | Follow-Up Studies | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | AIDS Vaccines - therapeutic use | Virus Latency - drug effects | AIDS Vaccines - adverse effects | Anti-HIV Agents - administration & dosage | HIV Infections - immunology | Drug Interactions | HIV-1 - physiology | Lymphocytes - immunology | Protein Processing, Post-Translational - drug effects | HIV-1 - isolation & purification | Adult | Anti-HIV Agents - therapeutic use | Female | Depsipeptides - therapeutic use | RNA, Viral - metabolism | Depsipeptides - adverse effects | Biomarkers - metabolism | Lymphocytes - metabolism | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Biomarkers - blood | Histones - blood | Acetylation - drug effects | HIV-1 - immunology | Virus Activation - drug effects | Lymphocytes - drug effects | HIV Infections - drug therapy | Histones - metabolism | Infusions, Intravenous | Viral Load - drug effects | Cohort Studies | Depsipeptides - administration & dosage | HIV Infections - metabolism | Studies | Plasma | HIV | Acquired immune deficiency syndrome | Cytokines | Lymphocytes | Curing | AIDS | Infections | Human immunodeficiency virus | Research | Drug therapy
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
BACKGROUND:The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described... 
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | INFECTIOUS DISEASES | lipids | high-density lipoprotein | BODY-COMPOSITION | IMMUNOLOGY | INSULIN SENSITIVITY | PROTEASE INHIBITORS | low-density lipoprotein | DIABETES-MELLITUS | NAIVE SUBJECTS | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | PLASMA-CONCENTRATIONS | highly active antiretroviral therapy | INFECTED PATIENTS | LOPINAVIR/RITONAVIR | women | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection
Journal Article
The Journal of infectious diseases, ISSN 1537-6613, 2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
... transcriptase inhibitor (NNRTI), efavirenz, in combination with tenofovir-disoproxil-fumarate and emtricitabine.1–4 However, efavirenz is associated with several adverse... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article